Ronald J Ellis

List of Publications by Year
in descending order

379 papers	25,811 citations	8172 76 h-index	8852 145 g-index
388 all docs	388 docs citations	388 times ranked	12451 citing authors

#	Article	IF	Citations
1	Objective and subjective sleep measures are associated with neurocognition in aging adults with and without HIV. Clinical Neuropsychologist, 2022, 36, 1352-1371.	1.5	16
2	Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 74, 1323-1328.	2.9	6
3	Reduced Gut Microbiome Diversity in People With HIV Who Have Distal Neuropathic Pain. Journal of Pain, 2022, 23, 318-325.	0.7	9
4	Frailty Syndrome Is Associated with Poorer Self-Reported Sleep Quality Among Older Persons with Human Immunodeficiency Virus. AIDS Research and Human Retroviruses, 2022, 38, 87-96.	0.5	2
5	Polypharmacy in older adults with HIV infection: Effects on the brain. Journal of the American Geriatrics Society, 2022, 70, 924-927.	1.3	2
6	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain, 2022, 145, 2206-2213.	3.7	1
7	Fatigue is associated with worse cognitive and everyday functioning in older persons with HIV. Aids, 2022, 36, 763-772.	1.0	0
8	Higher Cerebrospinal Fluid Soluble Urokinase-type Plasminogen Activator Receptor, But Not Interferon Î³-inducible Protein 10, Correlate With Higher Working Memory Deficits. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 106-114.	0.9	3
9	The impacts of HIV infection, age, and education on functional brain networks in adults with HIV. Journal of NeuroVirology, 2022, 28, 265-273.	1.0	3
10	Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 97-105.	0.9	3
11	CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study. Journal of NeuroVirology, 2022, 28, 162-167.	1.0	5
12	Polygenic networks in peripheral leukocytes indicate patterns associated with HIV infection and context-dependent effects of cannabis use. Brain, Behavior, & Immunity - Health, 2022, 20, 100414.	1.3	4
13	Main lymphocyte subpopulations in cerebrospinal fluid and peripheral blood in HIV-1 subtypes C and B. Journal of NeuroVirology, 2022, 28, 291-304.	1.0	3
14	Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluid. Journal of NeuroVirology, 2022, 28, 281-290.	1.0	3
15	Cognitive and Physiologic Reserve Independently Relate to Superior Neurocognitive Abilities in Adults Aging With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 440-448.	0.9	1
16	Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years. Brain, Behavior, & Immunity - Health, 2022, 21, 100437.	1.3	2
17	Soluble CD14 is subtype-dependent in serum but not in cerebrospinal fluid in people with HIV. Journal of Neuroimmunology, 2022, 366, 577845.	1.1	3
18	Toward Composite Pain Biomarkers of Neuropathic Painâ€"Focus on Peripheral Neuropathic Pain. Frontiers in Pain Research, 2022, 3, .	0.9	11

#	Article	IF	Citations
19	Association Between VACS Index and Health-Related Quality of Life in Persons with HIV: Moderating Role of Fruit and Vegetable Consumption. International Journal of Behavioral Medicine, 2022, , 1.	0.8	0
20	Cingulate transcranial direct current stimulation in adults with HIV. PLoS ONE, 2022, 17, e0269491.	1.1	0
21	Higher cerebrospinal fluid biomarkers of neuronal injury in HIV-associated neurocognitive impairment. Journal of NeuroVirology, 2022, 28, 438-445.	1.0	9
22	Longitudinal evaluation of <scp>neurologicâ€post</scp> acute sequelae <scp>SARSâ€CoV</scp>â€2 infection symptoms. Annals of Clinical and Translational Neurology, 2022, 9, 995-1010.	1.7	22
23	Beneficial Effects of Cannabis on Bloodâ€“Brain Barrier Function in Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 124-129.	2.9	20
24	Low Neuroactive Steroids Identifies a Biological Subtype of Depression in Adults with Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 1601-1611.	1.9	15
25	Cannabis and the Gutâ€“Brain Axis Communication in HIV Infection. Cannabis and Cannabinoid Research, 2021, 6, 92-104.	1.5	8
26	Glucan rich nutrition does not increase gut translocation of betaâ€glucan. Mycoses, 2021, 64, 24-29.	1.8	18
27	CNS Neurotoxicity of Antiretrovirals. Journal of NeuroImmune Pharmacology, 2021, 16, 130-143.	2.1	58
28	HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil. Journal of NeuroVirology, 2021, 27, 126-136.	1.0	12
29	Connectome-based prediction of global cognitive performance in people with HIV. NeuroImage: Clinical, 2021, 30, 102677.	1.4	7
30	Low CD4+ cell count nadir exacerbates the impacts of APOE Îµ4 on functional connectivity and memory in adults with HIV. Aids, 2021, 35, 727-736.	1.0	14
31	Plasma Citrate and Succinate Are Associated With Neurocognitive Impairment in Older People With HIV. Clinical Infectious Diseases, 2021, 73, e765-e772.	2.9	6
32	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. Pain Medicine, 2021, 22, 1850-1856.	0.9	3
33	Cannabis use is not associated with increased balance disturbances in HIV-infected individuals. Journal of Cannabis Research, 2021, 3, 3.	1.5	0
34	Baseline Neurocognitive Impairment (NCI) Is Associated With Incident Frailty but Baseline Frailty Does Not Predict Incident NCI in Older Persons With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 73, 680-688.	2.9	8
35	Detection of H3K4me3 Identifies NeuroHIV Signatures, Genomic Effects of Methamphetamine and Addiction Pathways in Postmortem HIV+ Brain Specimens that Are Not Amenable to Transcriptome Analysis. Viruses, 2021, 13, 544.	1.5	5
36	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. Journal of Neuroimmunology, 2021, 353, 577493.	1.1	4

#	Article	IF	Citations
37	Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology, 2021, 97, e156-e165.	1.5	5
38	Mitochondrial DNA haplogroups and domain-specific neurocognitive performance in adults with HIV. Journal of NeuroVirology, 2021, 27, 557-567.	1.0	2
39	Characterization of HIV-Associated Neurocognitive Impairment in Middle-Aged and Older Persons With HIV in Lima, Peru. Frontiers in Neurology, 2021, 12, 629257.	1.1	4
40	Depression is associated with hippocampal volume loss in adults with HIV. Human Brain Mapping, 2021, 42, 3750-3759.	1.9	9
41	IgG intrathecal synthesis in HIV-associated neurocognitive disorder (HAND) according to the HIV-1 subtypes and pattern of HIV RNA in CNS and plasma compartments. Journal of Neuroimmunology, 2021, 355, 577542.	1.1	7
42	Prevention of HIV-1 TAT Protein-Induced Peripheral Neuropathy and Mitochondrial Disruption by the Antimuscarinic Pirenzepine. Frontiers in Neurology, 2021, 12, 663373.	1.1	9
43	Higher CSF Ferritin Heavy-Chain (Fth1) and Transferrin Predict Better Neurocognitive Performance in People with HIV. Molecular Neurobiology, 2021, 58, 4842-4855.	1.9	2
44	Daily Cannabis Use is Associated With Lower CNS Inflammation in People With HIV. Journal of the International Neuropsychological Society, 2021, 27, 661-672.	1.2	19
45	Alterations of Brain Metabolites in Adults With HIV. Neurology, 2021, 97, e1085-e1096.	1.5	11
46	Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 1196-1204.	0.9	8
47	Cannabis and Inflammation in HIV: A Review of Human and Animal Studies. Viruses, 2021, 13, 1521.	1.5	17
48	Markers of Gut Barrier Function and Microbial Translocation Associate with Lower Gut Microbial Diversity in People with HIV. Viruses, 2021, 13, 1891.	1.5	17
49	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Research and Human Retroviruses, 2021, 37, 807-820.	0.5	1
50	Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV. Journal of NeuroVirology, 2021, 27, 160-167.	1.0	14
51	Association of painful human immunodeficiency virus distal sensory polyneuropathy with aberrant expectation of pain relief: functional magnetic resonance imaging evidence. Brain Communications, 2021, 3, fcab260.	1.5	3
52	A Haptoglobin Exon Copy Number Variant Associates With HIV-Associated Neurocognitive Impairment in European and African-Descent Populations. Frontiers in Genetics, 2021, 12, 756685.	1.1	1
53	Prior Methamphetamine Use Disorder History Does Not Impair Interoceptive Processing of Soft Touch in HIV Infection. Viruses, 2021, 13, 2476.	1.5	0
54	Identification of Youthful Neurocognitive Trajectories in Adults Aging with HIV: A Latent Growth Mixture Model. AIDS and Behavior, 2021, , 1.	1.4	1

#	Article	IF	Citations
55	Effect of Cannabis Use on Human Immunodeficiency Virus DNA During Suppressive Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 140-143.	2.9	21
56	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.2	15
57	Iron-regulatory genes are associated with Neuroimaging measures in HIV infection. Brain Imaging and Behavior, 2020, 14, 2037-2049.	1.1	5
58	Blood amyloid-Î² protein isoforms are affected by HIV-1 in a subtype-dependent pattern. Journal of NeuroVirology, 2020, 26, 3-13.	1.0	9
59	Characteristics of Motor Dysfunction in Longstanding Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 71, 1532-1538.	2.9	14
60	Low CD4 nadir linked to widespread cortical thinning in adults living with HIV. NeuroImage: Clinical, 2020, 25, 102155.	1.4	18
61	Pre-frailty predicts cognitive decline at 2-year follow-up in persons living with HIV. Journal of NeuroVirology, 2020, 26, 168-180.	1.0	11
62	Cannabis Exposure is Associated With a Lower Likelihood of Neurocognitive Impairment in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 56-64.	0.9	43
63	Baseline 10-Year Cardiovascular Risk Scores Predict Cognitive Function in Older Persons, and Particularly Women, Living With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2020, 71, 3079-3085.	2.9	11
64	Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. Brain, Behavior, and Immunity, 2020, 90, 353-363.	2.0	23
65	Antiretroviral drug concentrations in brain tissue of adult decedents. Aids, 2020, 34, 1907-1914.	1.0	34
66	Neurocytoskeleton Proteins in Cerebrospinal Fluid of People With HIV-1 Subtypes B and C. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 514-521.	0.9	1
67	Evidence for a novel subcortical mechanism for posterior cingulate cortex atrophy in HIV peripheral neuropathy. Journal of NeuroVirology, 2020, 26, 530-543.	1.0	7
68	Sex Differences in the Patterns and Predictors of Cognitive Function in HIV. Frontiers in Neurology, 2020, 11, 551921.	1.1	15
69	Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome. MSystems, 2020, 5, .	1.7	9
70	Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV. MSystems, 2020, 5, .	1.7	1
71	COMT val158met genotype alters the effects of methamphetamine dependence on dopamine and dopamine-related executive function: preliminary findings. Psychiatry Research, 2020, 292, 113269.	1.7	6
72	Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances. Journal of NeuroVirology, 2020, 26, 888-898.	1.0	3

#	Article	IF	Citations
73	Nucleic acid oxidation is associated with biomarkers of neurodegeneration in CSF in people with HIV. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	6
74	Cerebrospinal Fluid Norepinephrine and Neurocognition in HIV and Methamphetamine Dependence. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, e12-e22.	0.9	7
75	HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption. Journal of Virology, 2020, 94, .	1.5	5
76	The Effects of Lowâ€Risk Drinking on Neurocognition Among Older Persons Living With HIV as Compared to Those Without HIV. Alcoholism: Clinical and Experimental Research, 2020, 44, 1389-1399.	1.4	1
77	Recent cannabis use in HIV is associated with reduced inflammatory markers in CSF and blood. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	32
78	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Annals of Clinical and Translational Neurology, 2020, 7, 1166-1173.	1.7	12
79	Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape. Journal of NeuroVirology, 2020, 26, 241-251.	1.0	16
80	Lifetime Methamphetamine Use Disorder and Reported Sleep Quality in Adults Living with HIV. AIDS and Behavior, 2020, 24, 3071-3082.	1.4	7
81	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 617-625.	0.9	19
82	Frailty, Neurocognitive Impairment, or Both in Predicting Poor Health Outcomes Among Adults Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2019, 68, 131-138.	2.9	42
83	Physical Activity Is Associated With Lower Odds of Cognitive Impairment in Women but Not Men Living With Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2019, 219, 264-274.	1.9	9
84	Plasma (1â€‰â†'â€‰3)-Î²-d-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. Journal of NeuroVirology, 2019, 25, 837-843.	1.0	24
85	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	2.1	15
86	Gait Speed Decline Is Associated with Hemoglobin A1C, Neurocognitive Impairment, and Black Race in Persons with HIV. AIDS Research and Human Retroviruses, 2019, 35, 1065-1073.	0.5	6
87	A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. Cannabis and Cannabinoid Research, 2019, 4, 62-72.	1.5	10
88	HIV in the cART era and the mitochondrial: immune interface in the CNS. International Review of Neurobiology, 2019, 145, 29-65.	0.9	30
89	Mitochondrial biogenesis is altered in HIV+ brains exposed to ART: Implications for therapeutic targeting of astroglia. Neurobiology of Disease, 2019, 130, 104502.	2.1	29
90	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.2	28

#	Article	IF	Citations
91	Different roles of frontal versus striatal atrophy in HIVâ€associated neurocognitive disorders. Human Brain Mapping, 2019, 40, 3010-3026.	1.9	34
92	Brief Report: Body Mass Index and Cognitive Function Among HIV-1â€“Infected Individuals in China, India, and Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e30-e35.	0.9	8
93	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	1.0	44
94	Better executive function is independently associated with full HIV suppression during combination therapy. Aids, 2019, 33, 2309-2316.	1.0	1
95	Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice. Scientific Reports, 2019, 9, 17158.	1.6	26
96	Chronic Distal Sensory Polyneuropathy Is a Major Contributor to Balance Disturbances in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 568-573.	0.9	12
97	COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e148-e157.	0.9	8
98	Frailty in medically complex individuals with chronic HIV. Aids, 2019, 33, 1603-1611.	1.0	20
99	Effects of comorbidity burden and age on brain integrity in HIV. Aids, 2019, 33, 1175-1185.	1.0	35
100	Catechol-O-methyltransferase polymorphism Val158Met is associated with distal neuropathic pain in HIV-associated sensory neuropathy. Aids, 2019, 33, 1575-1582.	1.0	8
101	Risk of developing cerebral Î²-amyloid plaques with posttranslational modification among HIV-infected adults. Aids, 2019, 33, 2157-2166.	1.0	8
102	Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e95-e102.	0.9	16
103	Comparison of bead array and glass nanoreactor multi-analyte platforms for the evaluation of CNS and peripheral inflammatory markers during HIV infection. Journal of Immunological Methods, 2019, 465, 7-12.	0.6	2
104	Inflammation Relates to Poorer Complex Motor Performance Among Adults Living With HIV on Suppressive Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 15-23.	0.9	24
105	Extrapyramidal motor signs in older adults with HIV disease: frequency, 1-year course, and associations with activities of daily living and quality of life. Journal of NeuroVirology, 2019, 25, 162-173.	1.0	10
106	Psychosocial Correlates of Frailty Among HIV-Infected and HIV-Uninfected Adults. Behavioral Medicine, 2019, 45, 210-220.	1.0	16
107	White matter damage, neuroinflammation, and neuronal integrity in HAND. Journal of NeuroVirology, 2019, 25, 32-41.	1.0	77
108	Neprilysin in the Cerebrospinal Fluid and Serum of Patients Infected With HIV1-Subtypes C and B. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 248-256.	0.9	5

#	Article	IF	Citations
109	Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil. Journal of NeuroVirology, 2018, 24, 339-349.	1.0	17
110	Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1â€"Infected Adults in the United States. Clinical Infectious Diseases, 2018, 67, 1182-1190.	2.9	52
111	Clinical Reasoning: A 22-year-old postpartum woman with new-onset seizures and headache. Neurology, 2018, 90, e1631-e1635.	1.5	0
112	HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau. Journal of Neuroimmunology, 2018, 319, 13-18.	1.1	18
113	Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. Aids, 2018, 32, 1125-1135.	1.0	37
114	A Longitudinal Analysis of the Impact of Physical Activity on Neurocognitive Functioning Among HIV-Infected Adults. AIDS and Behavior, 2018, 22, 1562-1572.	1.4	34
115	Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. Journal of NeuroVirology, 2018, 24, 28-40.	1.0	17
116	Sex differences in HIV-associated cognitive impairment. Aids, 2018, 32, 2719-2726.	1.0	50
117	Effects of HIV Infection, methamphetamine dependence and age on cortical thickness, area and volume. NeuroImage: Clinical, 2018, 20, 1044-1052.	1.4	24
118	Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics. Journal of NeuroVirology, 2018, 24, 786-796.	1.0	6
119	Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS ONE, 2018, 13, e0199861.	1.1	32
120	Association of antiretroviral therapy with brain aging changes among HIV-infected adults. Aids, 2018, 32, 2005-2015.	1.0	31
121	Neurocognitive functioning predicts frailty index in HIV. Neurology, 2018, 91, e162-e170.	1.5	22
122	HIV Neurocognitive Diagnosis, Natural History, and Treatment. , 2018, , 730-740.		0
123	HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex. Pain Medicine, 2017, 18, pnw180.	0.9	17
124	Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalizationâ€"case study. Journal of NeuroVirology, 2017, 23, 460-473.	1.0	17
125	Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 332-338.	0.9	20
126	Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy. Aids, 2017, 31, 787-795.	1.0	19

#	Article	IF	Citations
127	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.1	26
128	Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 48-54.	0.9	16
129	Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. Aids, 2017, 31, 1565-1571.	1.0	26
130	Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. Journal of Clinical Microbiology, 2017, 55, 2544-2553.	1.8	16
131	Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2017, 65, 83-91.	2.9	33
132	Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals. Journal of NeuroVirology, 2017, 23, 283-289.	1.0	18
133	Can research at the end of life be a useful tool to advance HIV cure?. Aids, 2017, 31, 1-4.	1.0	39
134	Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated With Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 134-141.	0.9	11
135	Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 933-937.	1.9	67
136	Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. Aids, 2017, 31, 973-979.	1.0	22
137	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	3.1	30
138	Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. Fluids and Barriers of the CNS, 2017, 14, 11.	2.4	21
139	Higher Cystatin C Levels Are Associated With Neurocognitive Impairment in Older HIV+ Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 243-249.	0.9	6
140	Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 105-113.	1.9	67
141	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining â€œsymptomaticâ€•versus â€œasymptomaticâ€•HAND. Journal of NeuroVirology, 2017, 23, 67-78.	1.0	25
142	Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. PLoS Pathogens, 2017, 13, e1006112.	2.1	52
143	Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning. HIV/AIDS - Research and Palliative Care, 2016, 8, 93.	0.4	6
144	(1â†'3)-Î²-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy. Medicine (United States), 2016, 95, e3162.	0.4	35

#	Article	IF	Citations
145	Blood-CSF barrier and compartmentalization of CNS cellular immune response in HIV infection. Journal of Neuroimmunology, 2016, 301, 41-48.	1.1	24
146	Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B. Journal of NeuroVirology, 2016, 22, 715-724.	1.0	28
147	Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil. Journal of NeuroVirology, 2016, 22, 789-798.	1.0	9
148	Update and New Directions in Therapeutics for Neurological Complications of HIV Infections. Neurotherapeutics, 2016, 13, 471-476.	2.1	8
149	Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy. Virus Evolution, 2016, 2, vew020.	2.2	49
150	LatentToxoplasmaInfection and HigherToxoplasma gondiiImmunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults. Clinical Infectious Diseases, 2016, 63, 1655-1660.	2.9	18
151	Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment among HIV-infected Individuals. International Journal of Tryptophan Research, 2016, 9, IJTR.S36464.	1.0	42
152	The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study. Clinical Infectious Diseases, 2016, 63, 694-702.	2.9	27
153	Apolipoprotein E Îµ4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. Journal of NeuroVirology, 2016, 22, 607-614.	1.0	13
154	The impact of ethnicity/race on the association between the Veterans Aging Cohort Study (VACS) Index and neurocognitive function among HIV-infected persons. Journal of NeuroVirology, 2016, 22, 442-454.	1.0	25
155	HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiology of Disease, 2016, 86, 154-169.	2.1	79
156	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 2016, 22, 479-487.	1.0	26
157	Health-Related Everyday Functioning in the Internet Age: HIV-Associated Neurocognitive Disorders Disrupt Online Pharmacy and Health Chart Navigation Skills. Archives of Clinical Neuropsychology, 2016, 31, acv090.	0.3	31
158	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	1.9	31
159	Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. Journal of NeuroVirology, 2016, 22, 191-200.	1.0	31
160	Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults. AIDS Research and Human Retroviruses, 2016, 32, 271-278.	0.5	9
161	European Mitochondrial DNA Haplogroups are Associated with Cerebrospinal Fluid Biomarkers of Inflammation in HIV Infection. Pathogens and Immunity, 2016, 1, 330.	1.4	7
162	Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART. Scientific Reports, 2015, 5, 17094.	1.6	19

#	Article	IF	Citations
163	Cerebrospinal Fluid (CSF) CD8+ T-Cells That Express Interferon-Gamma Contribute to HIV Associated Neurocognitive Disorders (HAND). PLoS ONE, 2015, 10, e0116526.	1.1	65
164	Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR. PLoS ONE, 2015, 10, e0139510.	1.1	22
165	Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain, 2015, 156, 731-739.	2.0	31
166	Antiretroviral therapy reduces neurodegeneration in HIV infection. Aids, 2015, 29, 323-330.	1.0	29
167	Incident major depressive episodes increase the severity and risk of apathy in HIV infection. Journal of Affective Disorders, 2015, 175, 475-480.	2.0	9
168	Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. European Neuropsychopharmacology, 2015, 25, 141-150.	0.3	37
169	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clinical Infectious Diseases, 2015, 61, 1476-1484.	2.9	27
170	Reply to Haddow, et al.. Clinical Infectious Diseases, 2015, 60, 1442-3.	2.9	0
171	HIV Infection Is Associated with Attenuated Frontostriatal Intrinsic Connectivity: A Preliminary Study. Journal of the International Neuropsychological Society, 2015, 21, 203-213.	1.2	74
172	Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 281-288.	0.9	73
173	Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis ofÂIndividual Patient Data. Journal of Pain, 2015, 16, 1221-1232.	0.7	198
174	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clinical Infectious Diseases, 2015, 60, 473-480.	2.9	326
175	Brain Abscess following Rituximab Infusion in a Patient with Pemphigus Vulgaris. American Journal of Case Reports, 2015, 16, 65-68.	0.3	9
176	HIV Neurocognitive Diagnosis, Natural History, and Treatment. , 2015, , 1-11.		0
177	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	1.1	29
178	Cerebrospinal fluid can be used for HIV genotyping when it fails in blood. Arquivos De Neuro-Psiquiatria, 2014, 72, 506-509.	0.3	4
179	Portable lactate analyzer for measuring lactate in cerebrospinal fluid (CSF) and plasma ? method-comparison evaluations. Arquivos De Neuro-Psiquiatria, 2014, 72, 500-505.	0.3	1
180	Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. Journal of NeuroVirology, 2014, 20, 603-611.	1.0	11

#	Article	IF	Citations
181	Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood. Journal of NeuroVirology, 2014, 20, 496-504.	1.0	25
182	Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 854-866.	0.8	42
183	HIV and Aging: Effects on the Central Nervous System. Seminars in Neurology, 2014, 34, 027-034.	0.5	43
184	The Veterans Aging Cohort Study Index is Associated With Concurrent Risk for Neurocognitive Impairment. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 190-197.	0.9	65
185	HIV protease inhibitor exposure predicts cerebral small vessel disease. Aids, 2014, 28, 1297-1306.	1.0	75
186	Self-Predictions of Prospective Memory in HIV-Associated Neurocognitive Disorders: Evidence of a Metamemory Deficit. Archives of Clinical Neuropsychology, 2014, 29, 818-827.	0.3	17
187	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. American Journal of Epidemiology, 2014, 180, 297-307.	1.6	35
188	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.5	255
189	NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-associated Distal Sensory Polyneuropathy. Clinical Journal of Pain, 2014, 30, 134-142.	0.8	33
190	The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Research, 2014, 218, 201-208.	1.7	11
191	HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. Journal of NeuroVirology, 2014, 20, 209-218.	1.0	27
192	Randomized Trial of Central Nervous Systemâ€“Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder. Clinical Infectious Diseases, 2014, 58, 1015-1022.	2.9	110
193	Acute HIV infection presenting as fulminant meningoencephalitis with massive CSF viral replication. Neurology: Clinical Practice, 2014, 4, 256-259.	0.8	2
194	Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. Journal of NeuroVirology, 2014, 20, 371-379.	1.0	5
195	â€œFrontal systemsâ€•behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency. Psychiatry Research, 2014, 215, 208-216.	1.7	37
196	Altered Functional Response to Risky Choice in HIV Infection. PLoS ONE, 2014, 9, e111583.	1.1	26
197	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	1.0	38
198	Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2013, 19, 150-156.	1.0	57

#	Article	IF	Citations
199	Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. Journal of NeuroVirology, 2013, 19, 65-74.	1.0	72
200	Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. Journal of NeuroVirology, 2013, 19, 410-417.	1.0	64
201	Alterations in the Levels of Vesicular Trafficking Proteins Involved in HIV Replication in the Brains and CSF of Patients with HIV-associated Neurocognitive Disorders. Journal of NeuroImmune Pharmacology, 2013, 8, 1197-1209.	2.1	12
202	Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life. AIDS Patient Care and STDs, 2013, 27, 5-16.	1.1	267
203	Implications of apathy and depression for everyday functioning in HIV/AIDS in Brazil. Journal of Affective Disorders, 2013, 150, 1069-1075.	2.0	42
204	Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. Journal of NeuroVirology, 2013, 19, 550-556.	1.0	50
205	Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. Journal of NeuroVirology, 2013, 19, 557-564.	1.0	45
206	Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology, 2013, 80, 1415-1423.	1.5	160
207	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. Journal of Antimicrobial Chemotherapy, 2013, 68, 684-689.	1.3	34
208	Etravirine in CSF is highly protein bound. Journal of Antimicrobial Chemotherapy, 2013, 68, 1161-1168.	1.3	25
209	Human Immunodeficiency Virus Infection Heightens Concurrent Risk of Functional Dependence in Persons With Long-Term Methamphetamine Use. Journal of Addiction Medicine, 2013, 7, 255-263.	1.4	55
210	Concurrent Classification Accuracy of the HIV Dementia Scale for HIV-Associated Neurocognitive Disorders in the CHARTER Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 36-42.	0.9	24
211	Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. Aids, 2013, 27, 1387-1395.	1.0	235
212	Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology, 2012, 78, 485-492.	1.5	168
213	Implications of Apathy for Everyday Functioning Outcomes in Persons Living with HIV Infection. Archives of Clinical Neuropsychology, 2012, 27, 520-531.	0.3	67
214	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2012, 56, 1985-1989.	1.4	14
215	Synergistic Effects of HIV Infection and Older Age on Daily Functioning. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 341-348.	0.9	116
216	Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 376-381.	0.9	72

#	Article	IF	Citations
217	Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. Aids, 2012, 26, 890-893.	1.0	16
218	HIV-Infected Individuals with Co-occurring Bipolar Disorder Evidence Poor Antiretroviral and Psychiatric Medication Adherence. AIDS and Behavior, 2012, 16, 2257-2266.	1.4	45
219	Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology, 2012, 433, 498-505.	1.1	11
220	HIV peripheral neuropathy progression: protection with glucose-lowering drugs?. Journal of NeuroVirology, 2012, 18, 428-433.	1.0	16
221	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	1.0	24
222	Health-Related Quality of Life â€˜Well-Being' in HIV Distal Neuropathic Pain is More Strongly Associated with Depression Severity than with Pain Intensity. Psychosomatics, 2012, 53, 380-386.	2.5	40
223	Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 1504-1513.	0.6	83
224	Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers. PLoS ONE, 2012, 7, e31031.	1.1	19
225	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	1.0	15
226	Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. Journal of NeuroVirology, 2012, 18, 191-199.	1.0	41
227	A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Research, 2012, 1431, 46-52.	1.1	69
228	Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 505-522.	0.8	143
229	Testâ€“retest stability of calibrated BOLD-fMRI in HIVâˆ' and HIV+ subjects. NeuroImage, 2011, 54, 2156-2162.	2.1	47
230	Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. Journal of Clinical Virology, 2011, 52, 328-332.	1.6	11
231	Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. Neurobehavioral HIV Medicine, 2011, 3, 41.	2.0	21
232	CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. Aids, 2011, 25, 1747-1751.	1.0	345
233	Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. Aids, 2011, 25, 357-365.	1.0	190
234	A neuropsychological investigation of multitasking in HIV infection: Implications for everyday functioning.. Neuropsychology, 2011, 25, 511-519.	1.0	69

#	Article	IF	Citations
235	Incidence of Post-Dural Puncture Headache in Research Volunteers. Headache, 2011, 51, 1503-1510.	1.8	79
236	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology, 2011, 215, 697-707.	1.5	31
237	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	1.0	1,327
238	Neurocognitive functioning in acute or early HIV infection. Journal of NeuroVirology, 2011, 17, 50-57.	1.0	40
239	Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 63-69.	1.0	79
240	Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. Journal of NeuroVirology, 2011, 17, 239-247.	1.0	35
241	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	1.0	158
242	Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. Journal of NeuroVirology, 2011, 17, 327-340.	1.0	33
243	HIV and Chronic Methamphetamine Dependence Affect Cerebral Blood Flow. Journal of NeuroImmune Pharmacology, 2011, 6, 409-419.	2.1	35
244	Are Time- and Event-based Prospective Memory Comparably Affected in HIV Infection?. Archives of Clinical Neuropsychology, 2011, 26, 250-259.	0.3	30
245	Soluble CD163 Made by Monocyte/Macrophages Is a Novel Marker of HIV Activity in Early and Chronic Infection Prior to and After Anti-retroviral Therapy. Journal of Infectious Diseases, 2011, 204, 154-163.	1.9	286
246	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy, 2011, 66, 354-357.	1.3	82
247	Quantification of cerebrospinal fluid lactic acid in the differential diagnosis between HIV chronic meningitis and opportunistic meningitis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 891-6.	1.4	16
248	Script Generation of Activities of Daily Living in HIV-Associated Neurocognitive Disorders. Journal of the International Neuropsychological Society, 2011, 17, 740-745.	1.2	7
249	Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. Aids, 2011, 25, F1-F6.	1.0	29
250	Peripheral neuropathy in HIV: prevalence and risk factors. Aids, 2011, 25, 919-928.	1.0	171
251	Misremembering Future Intentions in Methamphetamine-Dependent Individuals. Clinical Neuropsychologist, 2011, 25, 269-286.	1.5	30
252	Minocycline treatment for HIV-associated cognitive impairment. Neurology, 2011, 77, 1135-1142.	1.5	74

#	Article	IF	Citations
253	Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 326-334.	0.8	17
254	Viral Dynamics. , 2011, , 847-855.		0
255	Memantine for AIDS Dementia Complex: Open-Label Report of ACTG 301. HIV Clinical Trials, 2010, 11, 59-67.	2.0	57
256	Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. Journal of NeuroVirology, 2010, 16, 6-12.	1.0	34
257	Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain, 2010, 151, 732-736.	2.0	38
258	HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurology, 2010, 10, 60.	0.8	62
259	Molecular epidemiology of HIV-1 clades in Southern Brazil. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 1044-1049.	0.8	13
260	HIV Infection and Aging Independently Affect Brain Function as Measured by Functional Magnetic Resonance Imaging. Journal of Infectious Diseases, 2010, 201, 336-340.	1.9	145
261	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virusâ€“Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.9	347
262	Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1. Antimicrobial Agents and Chemotherapy, 2010, 54, 5156-5160.	1.4	63
263	HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology, 2010, 75, 2087-2096.	1.5	2,036
264	HIV and antiretroviral therapy: Impact on the central nervous system. Progress in Neurobiology, 2010, 91, 185-187.	2.8	14
265	Memantine for AIDS Dementia Complex: Open-Label Report of ACTG 301. HIV Clinical Trials, 2010, 11, 59-67.	2.0	2
266	Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 45-55.	2.9	138
267	Resting cerebral blood flow. Neurology, 2009, 73, 702-708.	1.5	120
268	Role of metabolic syndrome components in HIV-associated sensory neuropathy. Aids, 2009, 23, 2317-2322.	1.0	26
269	Low atazanavir concentrations in cerebrospinal fluid. Aids, 2009, 23, 83-87.	1.0	112
270	Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids, 2009, 23, 1359-1366.	1.0	305

#	Article	IF	Citations
271	Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology, 2009, 73, 342-348.	1.5	268
272	Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. Virology, 2009, 385, 204-208.	1.1	29
273	Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology, 2009, 394, 243-248.	1.1	10
274	HIV Infection and the Central Nervous System: A Primer. Neuropsychology Review, 2009, 19, 144-151.	2.5	88
275	White matter tract injury and cognitive impairment in human immunodeficiency virusâ€“infected individuals. Journal of NeuroVirology, 2009, 15, 187-195.	1.0	131
276	Role of metabolic syndrome components in human immunodeficiency virusâ€“associated stroke. Journal of NeuroVirology, 2009, 15, 249-256.	1.0	18
277	Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of NeuroVirology, 2009, 15, 360-370.	1.0	176
278	Cerebrospinal Fluid Proteomics Reveals Potential Pathogenic Changes in the Brains of SIV-Infected Monkeys. Journal of Proteome Research, 2009, 8, 2253-2260.	1.8	32
279	Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. Neuropsychopharmacology, 2009, 34, 672-680.	2.8	392
280	Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. Aids, 2009, 23, 907-915.	1.0	94
281	Timing is everything: Antiretroviral nonadherence is associated with impairment in time-based prospective memory. Journal of the International Neuropsychological Society, 2009, 15, 42-52.	1.2	119
282	Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 169-183.	1.1	14
283	Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2009, 17, 46-56.	2.9	42
284	Estimating selection pressures on HIVâ€1 using phylogenetic likelihood models. Statistics in Medicine, 2008, 27, 4779-4789.	0.8	19
285	Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Annals of Neurology, 2008, 64, 566-572.	2.8	147
286	Cognitive changes in asymptomatic drug-naÃ¯ve human immunodeficiency virus type 1 clade C infection. Journal of NeuroVirology, 2008, 14, 480-485.	1.0	6
287	Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. Journal of NeuroVirology, 2008, 14, 550-557.	1.0	13
288	Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Medicine, 2008, 9, 731-737.	1.0	11

#	Article	IF	Citations
289	Two-year prospective study of major depressive disorder in HIV-infected men. Journal of Affective Disorders, 2008, 108, 225-234.	2.0	97
290	Variable patterns of neuropsychological performance in HIV-1 infection. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 613-626.	0.8	103
291	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.9	777
292	Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 83-90.	0.8	49
293	Osteopontin Is Increased in HIVâ€Associated Dementia. Journal of Infectious Diseases, 2008, 198, 715-722.	1.9	51
294	Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. International Review of Psychiatry, 2008, 20, 89-93.	1.4	43
295	Cognitive mechanisms of switching in HIV-associated category fluency deficits. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 797-804.	0.8	38
296	Better Biomarkers Are Needed to Improve the Management of the Neurologic Complications of HIV Infection. Clinical Infectious Diseases, 2008, 46, 1940-1941.	2.9	0
297	Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 805-815.	0.8	30
298	Psychometric Characteristics of the Memory for Intentions Screening Test. Clinical Neuropsychologist, 2008, 22, 864-878.	1.5	101
299	Evidence-Based Treatment for HIV-Associated Dementia and Cognitive Impairment: Why So Little. PLOS Clinical Trials, 2007, 2, e15.	3.5	3
300	Proton MRS and Neuropsychological Correlates in AIDS Dementia Complex: Evidence of Subcortical Specificity. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 283-292.	0.9	75
301	HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. Aids, 2007, 21, 1109-1117.	1.0	69
302	Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids, 2007, 21, 1877-1886.	1.0	141
303	Dementia and Neurocognitive Disorders Due to HIV-1 Infection. Seminars in Neurology, 2007, 27, 086-092.	0.5	249
304	A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology, 2007, 69, 1314-1321.	1.5	82
305	Pathogenesis of Hepatitis C Virus Coinfection in the Brains of Patients Infected with HIV. Journal of Infectious Diseases, 2007, 196, 361-370.	1.9	125
306	Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid. Clinical Infectious Diseases, 2007, 45, 1511-1517.	2.9	40

#	Article	IF	Citations
307	The prevalence and incidence of neurocognitive impairment in the HAART era. Aids, 2007, 21, 1915-1921.	1.0	539
308	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. HIV Clinical Trials, 2007, 8, 437-446.	2.0	30
309	The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 266-276.	0.8	65
310	HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nature Reviews Neuroscience, 2007, 8, 33-44.	4.9	458
311	Neuropathologic confirmation of definitional criteria for human immunodeficiency virusâ€“associated neurocognitive disorders. Journal of NeuroVirology, 2007, 13, 23-28.	1.0	69
312	NeuroAIDS in Brazil. Journal of NeuroVirology, 2007, 13, 89-96.	1.0	5
313	Neuropsychological deficits in human immunodeficiency virus type 1 clade Câ€“seropositive adults from South India. Journal of NeuroVirology, 2007, 13, 195-202.	1.0	100
314	The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. Journal of NeuroImmune Pharmacology, 2007, 2, 120-127.	2.1	38
315	Clinical Trials in HIV CNS Disease and Treatment Management. Journal of NeuroImmune Pharmacology, 2007, 2, 20-25.	2.1	2
316	Meeting Practical Challenges of a Trial Involving a Multitude of Treatment Regimens: An Example of a Multi-Center Randomized Controlled Clinical Trial in NeuroAIDS. Journal of NeuroImmune Pharmacology, 2007, 2, 97-104.	2.1	13
317	Low CSF Leptin Levels are Associated with Worse Learning and Memory Performance in HIV-infected Men. Journal of NeuroImmune Pharmacology, 2007, 2, 352-358.	2.1	16
318	Prospective Memory in HIV-1 Infection. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 536-548.	0.8	119
319	A battery approach for measuring neuropsychological change. Archives of Clinical Neuropsychology, 2006, 21, 83-89.	0.3	62
320	Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. Aids, 2006, 20, 879-887.	1.0	192
321	Lithium improves HIV-associated neurocognitive impairment. Aids, 2006, 20, 1885-1888.	1.0	89
322	Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virusâ€“infected patients. Journal of NeuroVirology, 2006, 12, 100-107.	1.0	70
323	Valproic acid does not affect markers of human immunodeficiency virus disease progression. Journal of NeuroVirology, 2006, 12, 403-406.	1.0	14
324	Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology, 2006, 179, 180-185.	1.1	17

#	Article	IF	Citations
325	Screening for major depression in persons with HIV infection: the concurrent predictive validity of the Profile of Mood States Depression-Dejection Scale. International Journal of Methods in Psychiatric Research, 2006, 15, 75-82.	1.1	36
326	Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain, 2006, 129, 1872-1883.	3.7	94
327	Characterization of Interference with 6 Commercial Î”9-Tetrahydrocannabinol Immunoassays by Efavirenz (Glucuronide) in Urine. Clinical Chemistry, 2006, 52, 896-897.	1.5	34
328	Visual Attention Deficits are Associated with Driving Accidents in Cognitively-Impaired HIV-Infected Individuals. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 13-28.	0.8	67
329	Action (verb) fluency: Testâ€“retest reliability, normative standards, and construct validity. Journal of the International Neuropsychological Society, 2005, 11, 408-415.	1.2	156
330	The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. Aids, 2005, 19, S72-S78.	1.0	114
331	Deficient Strategic Control of Verbal Encoding and Retrieval in Individuals With Methamphetamine Dependence.. Neuropsychology, 2005, 19, 35-43.	1.0	111
332	Clinical validation of the NeuroScreen. Journal of NeuroVirology, 2005, 11, 503-511.	1.0	65
333	Brain mitochondrial injury in human immunodeficiency virusâ€“seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. Journal of NeuroVirology, 2005, 11, 356-364.	1.0	158
334	Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. Journal of Neuroimmunology, 2005, 169, 144-152.	1.1	55
335	Temperament and risky behaviors: a pathway to HIV?. Journal of Affective Disorders, 2005, 85, 191-200.	2.0	37
336	Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy. Journal of Virology, 2005, 79, 1772-1788.	1.5	136
337	Effects of Methamphetamine Dependence and HIV Infection on Cerebral Morphology. American Journal of Psychiatry, 2005, 162, 1461-1472.	4.0	249
338	Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2005, 49, 2504-2506.	1.4	50
339	Altered P-Glycoprotein Expression in AIDS Patients with HIV Encephalitis. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1038-1047.	0.9	84
340	CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. Journal of Neuroimmunology, 2004, 157, 185-192.	1.1	45
341	The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. Journal of Neuroimmunology, 2004, 157, 193-196.	1.1	38
342	Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Annals of Neurology, 2004, 56, 416-423.	2.8	215

#	Article	IF	Citations
343	Regional patterns of brain metabolites in AIDS dementia complex. NeuroImage, 2004, 23, 928-935.	2.1	87
344	Correlation of In Vivo Neuroimaging Abnormalities With Postmortem Human Immunodeficiency Virus Encephalitis and Dendritic Loss. Archives of Neurology, 2004, 61, 369.	4.9	110
345	Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society, 2004, 10, 1-14.	1.2	380
346	Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. Journal of the International Neuropsychological Society, 2004, 10, 110-3.	1.2	90
347	The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society, 2004, 10, 317-31.	1.2	653
348	Effects of HIV-1 infection and aging on neurobehavioral functioning. Aids, 2004, 18, 27-34.	1.0	100
349	Retrograde Amnesia in Dementia: Comparison of HIV-Associated Dementia, Alzheimer's Disease, and Huntington's Disease.. Neuropsychology, 2004, 18, 692-699.	1.0	47
350	Effects of HIV-1 infection and aging on neurobehavioral functioning. Aids, 2004, , 27-34.	1.0	12
351	Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. Aids, 2004, 18 Suppl 1, S27-34.	1.0	67
352	Increased Human Immunodeficiency Virus Loads in Active Methamphetamine Users Are Explained by Reduced Effectiveness of Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 188, 1820-1826.	1.9	201
353	Human Immunodeficiency Virusâ€“1 RNA Levels in Cerebrospinal Fluid Exhibit a Set Point in Clinically Stable Patients Not Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 187, 1818-1821.	1.9	12
354	Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion. Archives of Neurology, 2003, 60, 1406.	4.9	63
355	Patterns of Selective Neuronal Damage in Methamphetamine-User AIDS Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 467-474.	0.9	115
356	Computerized reaction time battery versus a traditional neuropsychological battery: Detecting HIV-related impairments. Journal of the International Neuropsychological Society, 2003, 9, 64-71.	1.2	50
357	Progression to Neuropsychological Impairment in Human Immunodeficiency Virus Infection Predicted by Elevated Cerebrospinal Fluid Levels of Human Immunodeficiency Virus RNA. Archives of Neurology, 2002, 59, 923.	4.9	149
358	Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology, 2002, 58, 1439-1440.	1.5	16
359	Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. Aids, 2002, 16, 1019-1029.	1.0	141
360	Opioid blockade improves human recognition memory following physiological arousal. Pharmacology Biochemistry and Behavior, 2001, 70, 77-84.	1.3	25

#	Article	IF	Citations
361	Circuit party attendance, club drug use, and unsafe sex in gay men. Journal of Substance Abuse, 2001, 13, 119-126.	1.1	221
362	AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. Aids, 2001, 15, 1898-1899.	1.0	53
363	The impact of HIV-related neuropsychological dysfunction on driving behavior. Journal of the International Neuropsychological Society, 2000, 6, 854-854.	1.2	6
364	Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology, 2000, 54, 927-936.	1.5	193
365	Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2000, 44, 2173-2175.	1.4	47
366	Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. Neuroscience Letters, 1998, 254, 1-4.	1.0	34
367	Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease. Archives of Neurology, 1998, 55, 360.	4.9	67
368	Progressive Cerebral Volume Loss in Human Immunodeficiency Virus Infection. Archives of Neurology, 1998, 55, 161.	4.9	176
369	Neurocognitive Impairment Is an Independent Risk Factor for Death in HIV Infection. Archives of Neurology, 1997, 54, 416-424.	4.9	207
370	Types of Cerebrovascular Lesions Associated with Severe Cerebral Amyloid Angiopathy in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1997, 826, 493-497.	1.8	55
371	Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the volga German presenilin-2 mutation. Annals of Neurology, 1997, 42, 124-128.	2.8	40
372	Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Annals of Neurology, 1997, 42, 679-688.	2.8	314
373	Dendritic injury is a pathological substrate for human immunodeficiency virus?related cognitive disorders. Annals of Neurology, 1997, 42, 963-972.	2.8	463
374	Extrapyramidal Motor Signs in Clinically Diagnosed Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1996, 10, 103-114.	0.6	79
375	The HNRC 500-Neuropsychology of Hiv infection at different disease stages. Journal of the International Neuropsychological Society, 1995, 1, 231-251.	1.2	605
376	Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis. Muscle and Nerve, 1994, 17, 683-684.	1.0	13
377	Dichotic Asymmetries in Aging and Alcoholic Subjects. Alcoholism: Clinical and Experimental Research, 1990, 14, 863-871.	1.4	19
378	Alcoholism, aging, and functional cerebral asymmetries.. Psychological Bulletin, 1989, 106, 128-147.	5.5	138

#	Article	IF	Citations
379	Cognitive Deficits Related to Memory Impairments in Alcoholism. Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism, 1987, 5, 59-80.	0.4	42